China TAVR & TMV Market: Insights & Forecast with Potential Impact of COVID-19 (2023-2027)
China TAVR market is expected to reach US$2.60 billion in 2027, growing at a CAGR of 55.91%, for the duration spanning 2023-2027. While, the TMV market in China is forecasted to reach US$1832.05 million in 2027, rising at a CAGR of 146.50%, for the time period of 2023-2027. Factors such as growing prevalence of aortic stenosis, rise in approval of new TAVR products, rise in geriatric population and rapid urbanization would drive the growth of the market. However, the market growth would be challenged by risks associated with TAVR procedures and challenge of patient selection in TMVI. A few notable trends may include rising penetration of TAVR and TMV procedures, decline in prices of transcatheter mitral valve procedures, upcoming major TMVI products and rise in complications in open-heart surgery.
Currently, interventional heart valve therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening.
In particular, driven by China’s favorable policy encouraging innovative medical devices, a growing number of medical device companies have joined the competition of R&D of transcatheter heart valve repair and replacement products in China. Growth in the R&D activities among major players in the country would drive the new products launch and would propel the TAVR and TMV market in China.
Scope of the report:
The report provides a comprehensive analysis of the China TAVR and TMV Market
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The company profiles of leading players (Medtronic PLC, Edwards Lifesciences, Venus MedTech HangZhou Inc., MicroPort CardioFlow Medtech Corporation and Peijia Medical) are also presented in detail.
Key Target Audience:
TAVR and TMV Products Manufacturers
Raw Material Suppliers
End Users (Hospitals, Surgical centers and Medical Institutes)
Research and Development Firms
Medical Technology Companies
Investment Banks
Government Bodies & Regulating Authorities
Currently, interventional heart valve therapy is advancing rapidly and is considered as a safe and minimal invasive treatment suitable for elderly patients with high surgical risks, poor health and other complications. With technology development, indications for interventional therapy are broadening.
In particular, driven by China’s favorable policy encouraging innovative medical devices, a growing number of medical device companies have joined the competition of R&D of transcatheter heart valve repair and replacement products in China. Growth in the R&D activities among major players in the country would drive the new products launch and would propel the TAVR and TMV market in China.
Scope of the report:
The report provides a comprehensive analysis of the China TAVR and TMV Market
The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
The company profiles of leading players (Medtronic PLC, Edwards Lifesciences, Venus MedTech HangZhou Inc., MicroPort CardioFlow Medtech Corporation and Peijia Medical) are also presented in detail.
Key Target Audience:
TAVR and TMV Products Manufacturers
Raw Material Suppliers
End Users (Hospitals, Surgical centers and Medical Institutes)
Research and Development Firms
Medical Technology Companies
Investment Banks
Government Bodies & Regulating Authorities
1. OVERVIEW
1.1 Overview of Valvular Heart Diseases
1.2 Transcatheter Aortic Valve Replacement (TAVR)
1.3 Comparison Between Types of Valves in TAVR
1.4 Transcatheter Mitral Valve Replacement (TMVR)
1.5 Technical Challenges Between TAVR vs. TMVR
1.6 Manufacturing Process Of Artificial Valves
1.7 Current State and Unmet Needs of Interventional Therapy in China
2. COVID-19 IMPACT
2.1 Decline in Hospital Visits
2.2 Fall in Number of Merger & Acquisition (M&A) Deals
3. CHINA MARKET ANALYSIS
3.1 China Transcatheter Aortic Valve Replacement (TAVR) Market by Value
3.2 China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value
3.3 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume
3.4 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast
3.5 China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast
3.6 China Transcatheter Mitral Valve (TMV) Market Forecast by Value
3.6.1 China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value
3.6.2 China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value
3.7 China Transcatheter Mitral Valve (TMV) Treated Patient Volume Forecast
3.7.1 China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast
3.7.2 China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast
3.8 China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Prevalence of Aortic Stenosis
4.1.2 Rise in Approval of New TAVR Products
4.1.3 Rise in Geriatric Population
4.1.4 Rapid Urbanization
4.2 Key Trends
4.2.1 Rising Penetration of TAVR and TMV Procedures
4.2.2 Decline in Prices of Transcatheter Mitral Valve Procedures
4.2.3 Upcoming Major TMVI Products
4.2.4 Rise in Complications in Open-heart Surgery
4.3 Challenges
4.3.1 Risks Associated with TAVR Procedures
4.3.2 Challenge of Patient selection in TMVI
5. COMPANY PROFILES
5.1 Medtronic PLC
5.1.1 Business Overview
5.2 Edwards Lifesciences
5.2.1 Business Overview
5.3 Venus MedTech HangZhou Inc.
5.3.1 Business Overview
5.4 MicroPort CardioFlow Medtech Corporation
5.4.1 Business Overview
5.5 Peijia Medical
5.5.1 Business Overview
1.1 Overview of Valvular Heart Diseases
1.2 Transcatheter Aortic Valve Replacement (TAVR)
1.3 Comparison Between Types of Valves in TAVR
1.4 Transcatheter Mitral Valve Replacement (TMVR)
1.5 Technical Challenges Between TAVR vs. TMVR
1.6 Manufacturing Process Of Artificial Valves
1.7 Current State and Unmet Needs of Interventional Therapy in China
2. COVID-19 IMPACT
2.1 Decline in Hospital Visits
2.2 Fall in Number of Merger & Acquisition (M&A) Deals
3. CHINA MARKET ANALYSIS
3.1 China Transcatheter Aortic Valve Replacement (TAVR) Market by Value
3.2 China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value
3.3 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume
3.4 China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast
3.5 China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast
3.6 China Transcatheter Mitral Valve (TMV) Market Forecast by Value
3.6.1 China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value
3.6.2 China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value
3.7 China Transcatheter Mitral Valve (TMV) Treated Patient Volume Forecast
3.7.1 China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast
3.7.2 China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast
3.8 China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Growing Prevalence of Aortic Stenosis
4.1.2 Rise in Approval of New TAVR Products
4.1.3 Rise in Geriatric Population
4.1.4 Rapid Urbanization
4.2 Key Trends
4.2.1 Rising Penetration of TAVR and TMV Procedures
4.2.2 Decline in Prices of Transcatheter Mitral Valve Procedures
4.2.3 Upcoming Major TMVI Products
4.2.4 Rise in Complications in Open-heart Surgery
4.3 Challenges
4.3.1 Risks Associated with TAVR Procedures
4.3.2 Challenge of Patient selection in TMVI
5. COMPANY PROFILES
5.1 Medtronic PLC
5.1.1 Business Overview
5.2 Edwards Lifesciences
5.2.1 Business Overview
5.3 Venus MedTech HangZhou Inc.
5.3.1 Business Overview
5.4 MicroPort CardioFlow Medtech Corporation
5.4.1 Business Overview
5.5 Peijia Medical
5.5.1 Business Overview
LIST OF FIGURES
Types of Valvular Heart Diseases
Manufacturing Process Of Artificial Valves
Number of Hospital Visits in China (2019-2020)
Number of M&A deals in the Medical Device Sector in China (2019-2020)
China Transcatheter Aortic Valve Replacement (TAVR) Market by Value (2018-2022)
China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value (2023-2027)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume (2018-2022)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast (2023-2027)
China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast (2022-2027)
China Transcatheter Mitral Valve (TMV) Market Forecast by Value (2022-2027)
China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value (2023-2027)
China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value (2023-2027)
China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast (2023-2027)
China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast (2023-2027)
China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast (2022-2027)
China Prevalence of Aortic Stenosis (2018-2022)
China Population – Aged above 65 Years (2018-2022)
China Urban Population (2018-2022)
Penetration Rate of TAVR and TMV Procedures in China (2023-2027)
Average Prices of TMVI and TMVR in China (2023-2027)
Types of Valvular Heart Diseases
Manufacturing Process Of Artificial Valves
Number of Hospital Visits in China (2019-2020)
Number of M&A deals in the Medical Device Sector in China (2019-2020)
China Transcatheter Aortic Valve Replacement (TAVR) Market by Value (2018-2022)
China Transcatheter Aortic Valve Replacement (TAVR) Market Forecast by Value (2023-2027)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume (2018-2022)
China Transcatheter Aortic Valve Replacement (TAVR) Procedure Volume Forecast (2023-2027)
China Transcatheter Aortic Valve Replacement (TAVR) Treated Patient Volume Forecast (2022-2027)
China Transcatheter Mitral Valve (TMV) Market Forecast by Value (2022-2027)
China Transcatheter Mitral Valve Implantation (TMVI) Market Forecast by Value (2023-2027)
China Transcatheter Mitral Valve Replacement (TMVR) Market Forecast by Value (2023-2027)
China Transcatheter Mitral Valve Implantation (TMVI) Treated Patient Volume Forecast (2023-2027)
China Transcatheter Mitral Valve Replacement (TMVR) Treated Patient Volume Forecast (2023-2027)
China Transcatheter Mitral Valve (TMV) Procedure Volume Forecast (2022-2027)
China Prevalence of Aortic Stenosis (2018-2022)
China Population – Aged above 65 Years (2018-2022)
China Urban Population (2018-2022)
Penetration Rate of TAVR and TMV Procedures in China (2023-2027)
Average Prices of TMVI and TMVR in China (2023-2027)
LIST OF TABLES
Comparison Between Types of Valves in TAVR
Technical Challenges Between TAVR vs. TMVR
Major Approved and Marketed TAVR Products in China (2018-2022)
Upcoming Major TMVI Products
Risks Associated with TAVR Procedures
Comparison Between Types of Valves in TAVR
Technical Challenges Between TAVR vs. TMVR
Major Approved and Marketed TAVR Products in China (2018-2022)
Upcoming Major TMVI Products
Risks Associated with TAVR Procedures
